Dataset Information

A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic.

ABSTRACT: The pharmaceutical and biotechnology industries depend on findings from academic investigators prior to initiating programs to develop new diagnostic and therapeutic agents to benefit cancer patients. The success of these programs depends on the validity of published findings. This validity, represented by the reproducibility of published findings, has come into question recently as investigators from companies have raised the issue of poor reproducibility of published results from academic laboratories. Furthermore, retraction rates in high impact journals are climbing.To examine a microcosm of the academic experience with data reproducibility, we surveyed the faculty and trainees at MD Anderson Cancer Center using an anonymous computerized questionnaire; we sought to ascertain the frequency and potential causes of non-reproducible data. We found that ?50% of respondents had experienced at least one episode of the inability to reproduce published data; many who pursued this issue with the original authors were never able to identify the reason for the lack of reproducibility; some were even met with a less than "collegial" interaction.These results suggest that the problem of data reproducibility is real. Biomedical science needs to establish processes to decrease the problem and adjudicate discrepancies in findings when they are discovered.

SUBMITTER: Mobley A

PROVIDER: S-EPMC3655010 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic.

Mobley Aaron A Linder Suzanne K SK Braeuer Russell R Ellis Lee M LM Zwelling Leonard L

PloS one 20130515 5

<h4>Background</h4>The pharmaceutical and biotechnology industries depend on findings from academic investigators prior to initiating programs to develop new diagnostic and therapeutic agents to benefit cancer patients. The success of these programs depends on the validity of published findings. This validity, represented by the reproducibility of published findings, has come into question recently as investigators from companies have raised the issue of poor reproducibility of published results ...[more]

PMID: 23691000

Similar Datasets

Project description:BackgroundThe literature reports long time lags between the several processes involved in the translation of drug research and development into clinical application. To expedite these processes, translational research has emerged as a process that can be applied to reduce the lag between scientific discoveries and their practical application. Thus, the objective of this study was to estimate the time lag in translational research of biological drugs for the treatment of rheumatoid arthritis included in the Brazilian Unified Health System [Sistema Único de Saúde (SUS)].MethodsA descriptive retrospective study was conducted based on secondary data loaded by SUS users in public sources and systems to estimate the time lag between the publication of phase I clinical trial results to drug use in clinical settings. The dates of translational research activities were identified from markers and steps. Structured searches were conducted in the literature and reports from the National Commission for the Incorporation of Technologies in the SUS (Conitec) as well as from health authorities, and analyzed.ResultsBetween 2012 and 2019, SUS included five biological agents for the treatment of rheumatoid arthritis. The mean time lag from clinical development to use of these agents was 11.13 years (range, 8.57 to 12.90 years). The mean time lag for the stages of translational research were 5.30 (T1-basic research to clinical research), 5.08 (T2-clinical research to research synthesis), and 0.75 (T3-research synthesis to evidence-based practice) years. A shorter time lag was observed in the Brazilian case when it was possible to compare with other studies.ConclusionsThe estimated time lag of biological drugs used in the treatment of rheumatoid arthritis was determined based on the translational research steps model adapted to the Brazilian context. Brazil has instituted legal frameworks that set deadlines for sanitary registration, health technology assessment (HTA), and the availability of drugs in the SUS, thus, allowing for a reduced stage T2 time lag. Nevertheless, improvements are still required in stages T1 and T2, especially in publishing the results of clinical trials.

Project description:Temperature is one of the major environmental factors that people are exposed to on a daily basis, often in conditions that do not afford control. It is known that heat and cold can influence a person's productivity and performance in simple tasks. With respect to social cognition, it has also been suggested that temperature impacts on relatively high-level forms of decision-making. For instance, previous research demonstrated that cold temperature promotes utilitarian judgment in a moral dilemma task. This effect could be due to psychological processing, when a cool temperature primes a set of internal representations (associated with "coldness"). Alternatively, the promotion of utilitarian judgment in cold conditions could be due to physiological interference from temperature, impeding on social cognition. Refuting both explanations of psychological or physiological processing, however, it has been suggested that there may be problems of reproducibility in the literature on temperature modulating complex or abstract information processing. To examine the role of temperature in moral decision-making, we conducted a series of experiments using ambient and haptic temperature with careful manipulation checks and modified task methodology. Experiment 1 manipulated room temperature with cool (21°C), control (24°C) and hot (27°C) conditions and found only a cool temperature effect, promoting utilitarian judgment as in the previous study. Experiment 2 manipulated the intensity of haptic temperature but failed to obtain the cool temperature effect. Experiments 3 and 4 examined the generalizability of the cool ambient temperature effect with another moral judgment task and with manipulation of exposure duration. However, again there were no cool temperature effects, suggesting a lack of reproducibility. Despite successful manipulations of temperature in all four experiments, as measured in body temperature and the participants' self-reported perception, we found no systematic influence of temperature on moral decision-making. A Bayesian meta-analysis of the four experiments showed that the overall data tended to provide strong support in favor of the null hypothesis. We propose that, at least in the range of temperatures from 21 to 27°C, the cool temperature effect in moral decision-making is not a robust phenomenon.

Dataset Information

A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic.

Publications

A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets